Atom Bioscience Raises $45 Million In Series C Round Of Financing To Advance Development Of Small Molecule Drugs For Inflammatory And Metabolic Diseases
Atom Bioscience Raises $45 Million In Series C Round Of Financing To Advance Development Of Small Molecule Drugs For Inflammatory And Metabolic Diseases
01/05/22, 10:30 AM
Money raised
$45 million
Round Type
series c
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis (NASH), announced today the close of a $45 million Series C financing round to support a global Phase III clinical trial of ABP-671, the company’s lead small molecule drug for hyperuricemia and gout, and preclinical and clinical development of other pipeline products.
Company Info
Additional Info
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule, ABP-6016, has shown remarkable potency for treatment of non-alcoholic steatohepatitis (NASH) with an excellent safety profile. For more information please visit: http://www.atombp.com/en/